(1)Objectives: The objectives of this study is to evaluate the effect of silymarin on hepatic and platelet disorders in pregnant women with severe pre-eclampsia.
(2)Design: this randomized double-blind study is to carry out on two groups of 30 women with severe preeclampsia.
(3)Setting And Conducts:having entered the study, patients’ data and previous testing including the blood pressure, liver tests and platelet count are to extract from their history and is recorded in related lists. Both groups of patients are to undergo routine treatment for severe pre-eclampsia, including magnesium sulfate and hydralazine. In the intervention group, 3 and 24 hours after the termination of pregnancy, 70 mg silymarin is to be administered orally. In the control group at the same times, placebo is to be administered. Liver enzymes, LDH uric acid , direct Bilirubin, Total Bilirubin, ALP, ALT, AST, Cr, BUN, and urinary proteinuria and platelet count is to be repeated 12 , 36 and 60 hours after drug administration. Finally, two groups are to be compared in terms of blood pressure, proteinuria, liver enzyme levels and platelet counts.
(4)Participants: Inclusion criteria included termination of pregnancy due to severe preeclampsia, gestational age of 35 to 42 weeks at the time of pregnancy termination, absence of other diseases.
(5)Intervention: Administration of 70 mg of silymarin in the intervention group and administration of placebo in the control group 3 and 24 hours after termination of pregnancy.
(6)Main outcome masure:the number of platelets, AST, ALT, LDH